Characterizing diversity and antifungal resistance in immunocompromised ICU patients with respiratory infections
Official title: Unveiling the Fungal Frontier: Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections
Run by New Valley University · NCT06387667 · Data updated 2026-11-12
This study tests how diverse fungi and antifungal resistance appear in immunocompromised adults with pneumonia in the ICU.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | New Valley University Academic / other |
| Drugs / interventions | Rituximab |
| Locations | 1 site (Asyut) |
| Status | Recruiting |
| Started | December 1, 2025 |
| Main results expected | December 1, 2026 |
| Study ends | June 1, 2027 |
| Registry record updated | July 30, 2026 |
| Trial ID | NCT06387667 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with pneumonia in the ICU who are immunocompromised and have suspected fungal pneumonia or do not respond to antibiotics after 48 hours.
✕Probably not a fit
Patients without immunocompromise or fungal infection suspicion may not directly benefit from the results.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study enrolls adult ICU patients with pneumonia who are immunocompromised and have suspected fungal pneumonia. It collects routine clinical labs, imaging, and culture data to characterize the spectrum of fungal pathogens, their antifungal resistance patterns, and associated clinical factors. The goal is to better understand which patients are at risk and how resistance may vary by patient characteristics and environmental exposure. The analysis focuses on documenting Candida species distribution, resistance patterns, and correlations with immunosuppression, comorbidities, and hospital factors. This observational characterization informs future diagnostic and therapeutic strategies for invasive fungal infections in this high-risk population.
Why it matters
Potential benefit: Participants may contribute to knowledge that could improve future diagnosis and treatment of fungal infections in immunocompromised ICU patients.
How similar studies have gone: Previous work in ICU fungal infections has identified diverse Candida species and resistance trends; this study builds on that by focusing on immunocompromised ICU patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All adult patients (aged \>18 years old) admitted to the Assiut University Hospital's intensive care units with pneumonia and hospitalized patients who developed hospital-acquired or ventilator-associated pneumonia who don't respond to antibiotics for 48 hours or with a CT finding suspected for fungal pneumonia. Patients included must have at least one of the following conditions as a contributor to immunocompromise: * Pre-existing lung disease: IPF, COPD, or sarcoidosis. * Immunosuppression: Neutropenia, on corticosteroids, or immunosuppressive drugs, inherited or acquired immunodeficiency. * Underlying comorbidities: (Diabetes Mellitus,Chronic kidney disease, Liver cirrhosis) * Malignancy (Hematological or solid) Exclusion Criteria: * Patients refused to contribute to the study. * Unsatisfactory sample.
Where it's running
-
Assiut University
Asyut, Egypt Recruiting
Study contacts
- Study coordinator: Asmaa N Hussein, MD
- Email: asmaanady_1010@med.nvu.edu.eg
- Phone: +2 01065161752
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.